Featured Research

from universities, journals, and other organizations

New Agent Kills Influenza Virus, Prevents Infection In Mice

Date:
September 28, 1998
Source:
The University Of Michigan
Summary:
University of Michigan scientists have tested a new anti-microbial agent and found it to be a quick and efficient killer of influenza A virus in cell cultures and in the nasal passages of laboratory mice.

SAN DIEGO---University of Michigan scientists have tested a new anti-microbial agent and found it to be a quick and efficient killer of influenza A virus in cell cultures and in the nasal passages of laboratory mice.

Related Articles


"These are preliminary, small-scale studies, but the results indicate this material called BCTP shows promise as a new weapon against the influenza A virus," says James R. Baker Jr., M.D., professor of internal medicine and director of the Center for Biologic Nanotechnology in the U-M Medical School. "Its main advantages are its rapid killing action, lack of specificity and the fact that it is non-toxic to skin and mucous membranes."

A milky-white emulsion of tiny lipid droplets suspended in solvent, BCTP was developed by D. Craig Wright, M.D., chief research scientist at Novavax, Inc., and president of Novavax Biologics Division. Novavax is a bio-pharmaceutical company located in Columbia, Md. According to Wright, the material is made of water, soybean oil, Triton X 100 detergent and the solvent tri-n-butyl phosphate.

In presentations at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) on Sept. 26, U-M research associates Andrzej Myc and Jon D. Reuter presented results of preliminary studies evaluating BCTP's effect on influenza A. Both research studies were funded by the Defense Advanced Research Projects Agency (DARPA) and directed by Baker.

Myc's study used Madin Darby Canine Kidney cells, used by researchers to evaluate the toxic effects of viruses. Myc incubated MDCK cells with influenza A virus and five different formulations of Novavax lipid structures. Using two different assay techniques, Myc then measured the number of cells infected with the virus. While all five formulations slowed the spread of the virus, BCTP was the most potent, reducing viral antigen levels by 99.6 percent.

In Reuter's study, different liquids were inserted into the nasal passages of four groups of laboratory mice. Control mice in Group 1 were given ordinary saltwater. Group 2 received BCTP alone. Group 3 received live influenza A virus and Group 4 was given a mixture of influenza A and BCTP. Groups 1, 2 and 4 stayed healthy, while all the mice in Group 3 developed severe pneumonia and two out of three mice died before the conclusion of the study.

"We learned several important things from these preliminary studies. The first is that BCTP is a highly effective killing agent for the influenza virus both at the cellular level and in living animals. Equally important is that BCTP had no toxic effects on nasal or lung membranes," Baker says. "We've shown that if we treat the virus with BCTP as it enters the nasal passages, we can prevent infection in mice. The next step is to see whether we can administer BCTP and the virus separately and still prevent infection. And the final step, of course, is to see whether it works as well in people as it does in mice."

While influenza vaccines are relatively effective at preventing the flu, Baker says there is a need for alternate preventive agents. "Influenza vaccines are expensive, they only are effective against a few viral strains each year and it takes time for immunity to develop. BCTP appears to inactivate the virus on contact."

The research is funded by DARPA's Unconventional Pathogen Countermeasures Program. The U-M and Novavax have filed a patent application covering BCTP's use as a decontamination agent for various anti-microbial applications. Baker is a member of the Novavax scientific advisory board, but has no significant financial interest in the company.


Story Source:

The above story is based on materials provided by The University Of Michigan. Note: Materials may be edited for content and length.


Cite This Page:

The University Of Michigan. "New Agent Kills Influenza Virus, Prevents Infection In Mice." ScienceDaily. ScienceDaily, 28 September 1998. <www.sciencedaily.com/releases/1998/09/980928073202.htm>.
The University Of Michigan. (1998, September 28). New Agent Kills Influenza Virus, Prevents Infection In Mice. ScienceDaily. Retrieved October 25, 2014 from www.sciencedaily.com/releases/1998/09/980928073202.htm
The University Of Michigan. "New Agent Kills Influenza Virus, Prevents Infection In Mice." ScienceDaily. www.sciencedaily.com/releases/1998/09/980928073202.htm (accessed October 25, 2014).

Share This



More Health & Medicine News

Saturday, October 25, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Texas Nurse Nina Pham Cured of Ebola

Texas Nurse Nina Pham Cured of Ebola

AFP (Oct. 25, 2014) — An American nurse who contracted Ebola while caring for a Liberian patient in Texas has been declared free of the virus and will leave the hospital. Duration: 01:01 Video provided by AFP
Powered by NewsLook.com
IKEA Desk Converts From Standing to Sitting With One Button

IKEA Desk Converts From Standing to Sitting With One Button

Buzz60 (Oct. 24, 2014) — IKEA is out with a new convertible desk that can convert from a sitting desk to a standing one with just the push of a button. Jen Markham explains. Video provided by Buzz60
Powered by NewsLook.com
Ebola Protective Suits Being Made in China

Ebola Protective Suits Being Made in China

AFP (Oct. 24, 2014) — A factory in China is busy making Ebola protective suits for healthcare workers and others fighting the spread of the virus. Duration: 00:38 Video provided by AFP
Powered by NewsLook.com
WHO: Millions of Ebola Vaccine Doses by 2015

WHO: Millions of Ebola Vaccine Doses by 2015

AP (Oct. 24, 2014) — The World Health Organization said on Friday that millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines would start being tested in March. (Oct. 24) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
 
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:  

Breaking News:

Strange & Offbeat Stories

 

Health & Medicine

Mind & Brain

Living & Well

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:  

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile iPhone Android Web
Follow Facebook Twitter Google+
Subscribe RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins